SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

ubamatamab

REGN·REGENERON PHARMACEUTICALS, INC.
MIXED
Drug Impact Rating4/10
Trial phase
Phase 1/2
Time to market
Several years from potential approval. Regeneron is enrolling a potentially registrational single-arm cohort, plans FDA discussions in the coming months, and intends to initiate a confirmatory randomized Phase 3 trial; even under an accelerated path, market entry would likely be several years away.
Why 4/10
No hard dated catalyst (PDUFA, pivotal readout, or FDA decision) is scheduled in the next ~12 months; the next event is data from the potentially registrational ~100-patient LGSOC cohort or the planned confirmatory Phase 3 trial initiation, neither with a set date, and ubamatamab is a mid-stage drug at a large-cap diversified biotech, so the score stays at the default 4.
Actionable Insight MIXED

Watch for updates on the potentially registrational LGSOC cohort enrollment completion and any FDA meeting outcomes regarding the regulatory path. The next major catalyst would be data from the ~100-patient single-arm registrational cohort or the initiation of the planned confirmatory Phase 3 trial, though no specific date has been set.

Price Chart

Loading chart...

Executive Summary

Ubamatamab (REGN4018) is Regeneron's investigational MUC16xCD3 bispecific antibody being developed for ovarian cancer, with an initial focus on low-grade serous ovarian cancer (LGSOC). In October 2026, Regeneron reported early Phase 1/2 data at the IGCS 2026 meeting showing a 73% objective response rate (8 of 11 patients) and 11-month median progression-free survival at the 800 mg dose in heavily pretreated LGSOC patients. Regeneron is now enrolling a potentially registrational single-arm cohort of up to 100 patients and plans a confirmatory Phase 3 trial. The drug is still mid-stage with no dated regulatory catalyst, and Regeneron is a large-cap diversified biotech for which ubamatamab is one of many pipeline assets.

How It Works

Ubamatamab is a bispecific antibody, a type of engineered immunotherapy that works like a bridge. One arm of the antibody binds to MUC16, a protein abundant on the surface of ovarian cancer cells, and the other arm binds to CD3, a protein on immune T cells. This physically brings T cells next to the cancer cells and activates them to kill the tumor, using the body's own immune system rather than chemotherapy.

Trial Status

Ubamatamab is in an ongoing Phase 1/2 first-in-human trial (NCT03564340) in recurrent ovarian cancer and other MUC16+ cancers, alone or with cemiplimab. At IGCS 2026 (October 2026), Regeneron reported a 73% ORR and 11-month median PFS in 11 LGSOC patients treated at 800 mg. A potentially registrational LGSOC cohort of up to 100 patients is enrolling, and a separate multi-arm Phase 2 platform study (NCT06787612) is evaluating ubamatamab with or without additional agents in platinum-resistant ovarian cancer.

The Two-Sided Case

▲ Bull Case5
73% objective response rate and 11-month median progression-free survival at 800 mg in heavily pretreated recurrent LGSOC, a cancer with limited options and generally poor chemotherapy response
Regeneron is enrolling a potentially registrational single-arm cohort of up to 100 patients at the 800 mg dose, which could support an accelerated approval path if data hold up
MUC16 is a novel therapeutic target; LGSOC has uniformly high MUC16 expression, and ubamatamab appears to work without biomarker selection
Bispecific T-cell engager mechanism (bridging MUC16+ tumor cells to CD3+ T cells) is a proven oncology modality and Regeneron has its own anti-PD-1 (Libtayo/cemiplimab) for combination strategy
Additional development runway includes a multi-arm Phase 2 platform study (NCT06787612) in platinum-resistant ovarian cancer, expanding potential indications beyond LGSOC
▼ Bear Case5
Early data rests on only 11 evaluable patients (73% ORR, 8 of 11), a very small sample that could shrink in the larger ~100-patient cohort
Regeneron is a large-cap diversified biotech whose value spans Dupixent, Eylea, Libtayo and many other programs, so ubamatamab is a minor pipeline component and even a positive readout is a modest stock catalyst
Ovarian cancer is a crowded and competitive field: AbbVie's Elahere (mirvetuximab) is already approved in platinum-resistant disease, and other bispecifics/ADCs are in development
Drug is still in Phase 1/2 with no PDUFA date or pivotal readout scheduled; a mandatory confirmatory Phase 3 trial pushes any potential approval several years out
Regeneron's own stock dipped on the October 1, 2026 data release (per Seeking Alpha), suggesting the market read the small-sample result as less transformational than the headline

Upcoming Catalysts

  • Data from the potentially registrational single-arm LGSOC cohort (up to 100 patients), no specific date announced
  • FDA discussions on the LGSOC regulatory path, expected in the coming months per Regeneron
  • Initiation of the planned confirmatory randomized Phase 3 trial in LGSOC, planned but undated

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 9

Hover a chip for the title
1 investor.regeneron.com2 rttnews.com3 thebiotechtimes.com4 apexonco.com5 streetinsider.com6 taiwannews.com.tw7 seekingalpha.com8 cancernetwork.com9 troy-technical.com